Trevena shares are trading higher after the company announced today preclinical TRV045 data for long-term analgestic effect in prelinical model of neuropathic pain. Also, the company announced TRV045 results provided director for additional NIH-initiated studies in epilepsy prevention and treatment.
Portfolio Pulse from Benzinga Newsdesk
Trevena shares are trading higher after the company announced promising preclinical data for TRV045, showing long-term analgesic effects in a neuropathic pain model. Additionally, TRV045 results have led to further NIH-initiated studies in epilepsy prevention and treatment.
June 20, 2024 | 11:56 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Trevena shares are trading higher following the announcement of positive preclinical data for TRV045, which demonstrated long-term analgesic effects in a neuropathic pain model. The results have also prompted additional NIH-initiated studies in epilepsy prevention and treatment.
The positive preclinical data for TRV045 is a significant development for Trevena, indicating potential for long-term analgesic effects and opening new avenues for epilepsy treatment. This news is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100